Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Follow-Up Questions
Minerva Neurosciences Inc (NERV) の株価収益率はいくらですか？
Minerva Neurosciences Inc の株価収益率は 12.287 です。
Minerva Neurosciences Inc のCEOは誰ですか？
Dr. Remy Luthringer は Minerva Neurosciences Inc の Executive Chairman of the Board of Directors で、2014 から在籍しています。
NERV の株価パフォーマンスは？
NERV の現在の価格は $4.65 で、最終取引日から 0.94% decreased 変動しました。
Minerva Neurosciences Inc の主な事業テーマや業界は？
Minerva Neurosciences Inc は Biotechnology 業界、セクターは Health Care に属しています。
